CRISPR's Next Act: Pipeline Expands as CASGEVY Revenue Grows

ZUG, Switzerland and BOSTON – May 04, 2026 – CRISPR Therapeutics showcased significant progress in its evolution from a research pioneer to a commercial-stage biopharmaceutical powerhouse, reporting strong initial sales for its landmark gene-editing therapy, CASGEVY, and revealing major advancements across a diverse and ambitious clinical pipeline. The company's first-quarter 2026 financial update underscored a dual strategy: maximizing the reach of its first approved product while aggressively investing in next-generation therapies for autoimmune, cardiovascular, and rare diseases.

“The first quarter reflected continued execution across CRISPR Therapeutics’ platform,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer, in a statement. He emphasized that with a bolstered balance sheet and numerous upcoming milestones, “we believe 2026 will be a defining year for CRISPR Therapeutics.” The recent announcements suggest the company is laying the groundwork to move far beyond its initial success in blood disorders.

CASGEVY Builds Commercial Momentum

The headline achievement from the first quarter was the commercial performance of CASGEVY (exagamglogene autotemcel), the world's first approved CRISPR-based medicine. Developed in partnership with Vertex Pharmaceuticals, the therapy generated $43 million in revenue for the quarter. This figure represents a critical early validation of the market for a one-time treatment for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

According to the company, over 500 people globally have now started the CASGEVY treatment journey. While this number reflects patients at various stages—from initial referral to cell collection (apheresis)—data from commercial lead Vertex Pharmaceuticals provides a more granular view, indicating that dozens of patients have been infused in the U.S. and Europe, with many more currently undergoing the necessary pre-treatment conditioning. This highlights both the strong patient demand and the complex, multi-step logistics required to deliver the therapy.

Market access, a crucial hurdle for high-cost gene therapies, is also expanding. A new pricing agreement was secured in Germany, adding to a growing list of countries with reimbursement, including the U.K., Italy, and several nations in the Middle East. In the United States, an estimated 90% of eligible patients now have reimbursed access, a significant achievement that addresses early concerns about payer coverage. Further expanding its potential market, Vertex has submitted CASGEVY for U.S. regulatory approval in children ages 5 to 11, a submission bolstered by a rare FDA Commissioner's National Priority Voucher, which supports an accelerated review timeline.

Beyond Hemoglobinopathies: A Diversified Clinical Engine

While CASGEVY establishes the company's commercial footing, the Q1 update made it clear that CRISPR Therapeutics is looking toward a future defined by a much broader application of its technology. The company detailed significant progress in its cell therapy and in vivo editing programs, which aim to treat diseases directly inside the body.

A key area of expansion is in autoimmune disease, where the company is advancing zugocabtagene geleucel (zugo-cel), an allogeneic or "off-the-shelf" CAR-T therapy. Unlike autologous therapies that use a patient's own cells, zugo-cel is designed to be manufactured in advance, potentially reducing costs and wait times. The program has expanded into a third Phase 1 trial for a basket of autoimmune neurologic diseases, including progressive multiple sclerosis and stiff person syndrome. This is in addition to ongoing trials for rheumatology conditions like systemic lupus erythematosus (SLE) and hematologic autoimmune disorders, with over 14 patients dosed across the programs to date. Early data showing two SLE patients remaining in remission at 12 and 6 months, respectively, has generated considerable excitement about this approach.

Simultaneously, the company is pushing forward with a diversified portfolio of in vivo gene editing programs that use its proprietary lipid nanoparticle (LNP) delivery system to edit genes directly in the liver. Several of these programs are poised to enter the clinic in 2026, including:

• CTX340, targeting angiotensinogen (AGT) for refractory hypertension.
• CTX460, for alpha-1 antitrypsin deficiency (AATD), which notably uses the company's next-generation SyNTase™ editing platform.
• CTX310, targeting ANGPTL3 for severe hypertriglyceridemia and refractory hypercholesterolemia, which recently received FDA clearance to expand its ongoing trial into the U.S.

These programs represent a strategic shift toward treating more common conditions and demonstrate the versatility of the company's editing platform.

Financial Fortitude Fuels Ambitious Pipeline

Executing such a broad and ambitious R&D strategy requires substantial capital, and CRISPR Therapeutics has proactively strengthened its financial position. The company ended the first quarter with a formidable $2.44 billion in cash, cash equivalents, and marketable securities. This significant cash pile was primarily boosted by the net proceeds of $585.4 million from a convertible senior notes issuance in March 2026—a strategic move that provides capital without immediate shareholder dilution.

The company reported a net loss of $122.9 million for the quarter, an improvement over the $136.0 million loss from the same period in 2025. With a robust cash runway projected to last well into 2028, CRISPR Therapeutics is well-capitalized to fund its extensive pipeline through multiple critical clinical milestones. This financial strength is a key differentiator in the capital-intensive biotech sector, enabling the company to pursue high-risk, high-reward programs that could redefine medicine.

This financial stability allows the company to continue its collaborations, such as its partnership with Sirius Therapeutics on CTX611, an siRNA therapeutic for thromboembolic diseases, and to advance its wholly-owned regenerative medicine program for Type 1 diabetes. With multiple data readouts and clinical trial initiations expected in the second half of 2026, the company's strategic investments are poised to generate a steady stream of potentially value-creating news, further solidifying its leadership in the rapidly evolving field of gene-based medicine.